Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicorette actual-use studies support Waxman/Hatch exclusivity, SmithKline counsel argues..

This article was originally published in The Tan Sheet

Executive Summary

ACTUAL-USE STUDIES SUPPORT WAXMAN/HATCH EXCLUSIVITY, NICORETTE SPONSORS SmithKline Beecham and Hoechst Marion Roussel argue in a recent letter filed by the law firm Kleinfeld, Kaplan and Becker on behalf of the two companies. The letter points out that FDA representatives directed SmithKline and Marion Merrell Dow in 1993 to conduct two large scale actual-use studies to support the Rx-to-OTC switch of the nicotine gum smoking cessation aid.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel